As the means of inhibition of the CXCL8-IL-8 receptor axis are at hand, further studies on the therapeutic intervention seem warranted and may utilize a novel concept in AML therapy: to aim at the crucial AML microenvironment interaction rather than the leukemic cell itself. Here, CXCL8 is linked to acute myeloid leukemia.